Velarion · Company Intelligence
Compensation Brief
Fiscal year 2025 · Filings through 2026-09-18

Nutex Health (NUTX)

CEO Thomas Vo was paid $2,197,420 in fiscal year 2025, ↑ up 89.1% from fiscal year 2024 (SEC filing 0001628280-26-017681 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$2,197,420 ↑
Thomas Vo total, FY2025
—
CEO pay percentile vs peers
—
CEO-to-median pay ratio
94.79%
Say-on-pay support, latest vote

Track this company's pay every filing: join the Pro seat waitlist

Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year

A confirmation now and one email when Pro opens, and nothing else. Privacy

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Thomas Vo (Chief Executive Officer and Chairman of the Board), FY2025 total compensation $2,197,420 (base salary $1,000,000) [exec_comp, SEC accession 0001628280-26-017681, filed 2026-03-13]

Answered within 24 hours, every figure cited to its SEC filing. If our database cannot answer your question, you are refunded automatically.

NUTX's next annual pay disclosure, estimated December 22, 2026.est. Filing ↗

01

Summary Compensation Table — fiscal year 2025

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Thomas Vo$1,000,000$504,880$669,950$0$0$0$22,590$2,197,420
Chief Executive Officer and Chairman of the Board
Warren Hosseinion755,100382,430505,90500061,9861,705,421
President
Joshua DeTillio269,712297,500354,68400030,236952,132
Former Chief Operating Officer
Jon Bates350,000279,880239,66900054,656923,205
Chief Financial Officer
Michael Chang394,231129,880167,48800024,986716,585
Chief Medical Officer
Wesley Bamburg79,80825,00000001,164105,972
Chief Operating Officer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2025 totalFY2024 totalFY2023 totalΔ FY2024→2025
Thomas Vo$2,197,420$1,162,214$1,005,711↑ +1,035,206
Warren Hosseinion1,705,4211,243,432734,387↑ +461,989
Joshua DeTillio952,132810,664107,260↑ +141,468
Jon Bates923,205682,578453,713↑ +240,627
Michael Chang716,585298,876272,809↑ +417,709
Wesley Bamburg105,972———

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

You have just read Nutex Health's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper NUTX reports.

We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.

How we handle your data → Privacy

Companies that benchmark against NUTX
1 company names NUTX as a compensation peer

Each company listed discloses NUTX in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named NUTX in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.

01c

Board of directors

One page per director: the seat, the committees and the fee table, read for one person at a time.

DirectorRoleFY2025 total
Cheryl GrenasIndependent Director$271,869
Frank E. JaumotIndependent Director$152,269
Kelvin SpearsDirector—
Michael L. ReedLead Independent Director$277,608
Mitchell CreemFormer director (through FY2025)$188,768
Scott J. SaundersIndependent Director$268,346
02

Equity transactions since the proxy statement was filed

Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Pamela W. MontgomeryChief Legal Officer-Healthcare2026-03-13A79$89$7,021CommonForm 4 ↗
Kelvin SpearsDirector2026-03-17A1094945CommonForm 4 ↗
Warren HosseinionDirector2026-03-19A2529423,706CommonForm 4 ↗
Frank E. JaumotDirector2026-03-20A1509414,033CommonForm 4 ↗
Thomas T. VoDirector2026-04-09A184,07100CommonForm 4 ↗
Dividend-equivalent accruals2026-04-23—3,292——4 insiders, 4 accrual rows
Thomas T. VoDirector2026-05-28A75,74700CommonForm 4 ↗
Kelvin SpearsDirector2026-06-04A2,51900CommonForm 4 ↗
Michael L. ReedDirector2026-07-31A60300CommonForm 4 ↗
Scott J. SaundersDirector2026-07-31A60300CommonForm 4 ↗
Cheryl GrenasDirector2026-07-31A60300CommonForm 4 ↗
Frank E. JaumotDirector2026-07-31A60300CommonForm 4 ↗
Scott J. SaundersDirector2026-09-18D20321443,493CommonForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

View all 16 transactions
InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Pamela W. MontgomeryChief Legal Officer-Healthcare2026-03-13A79$89$7,021CommonForm 4 ↗
Kelvin SpearsDirector2026-03-17A1094945CommonForm 4 ↗
Warren HosseinionDirector2026-03-19A2529423,706CommonForm 4 ↗
Frank E. JaumotDirector2026-03-20A1509414,033CommonForm 4 ↗
Thomas T. VoDirector2026-04-09A184,07100CommonForm 4 ↗
Cheryl GrenasDirector2026-04-23A82300Derivative, Class A CommonForm 4 ↗
Frank E. JaumotDirector2026-04-23A82300Derivative, Class A CommonForm 4 ↗
Scott J. SaundersDirector2026-04-23A82300Derivative, Class A CommonForm 4 ↗
Michael L. ReedDirector2026-04-23A82300Derivative, Class A CommonForm 4 ↗
Thomas T. VoDirector2026-05-28A75,74700CommonForm 4 ↗
Kelvin SpearsDirector2026-06-04A2,51900CommonForm 4 ↗
Michael L. ReedDirector2026-07-31A60300CommonForm 4 ↗
Scott J. SaundersDirector2026-07-31A60300CommonForm 4 ↗
Cheryl GrenasDirector2026-07-31A60300CommonForm 4 ↗
Frank E. JaumotDirector2026-07-31A60300CommonForm 4 ↗
Scott J. SaundersDirector2026-09-18D20321443,493CommonForm 4 ↗
03

Grants of plan-based awards — fiscal year 2025

ExecutiveAwardGrant dateThresholdTargetGrantedMaximumGrant-date fair value
Joshua DeTillioPSU—————$354,684
Jon BatesPSU—————239,669
Michael ChangOTHER—————167,488
Thomas VoPSU—————669,950
Warren HosseinionPSU—————505,905
03b

Vehicle mix — grant-date fair value by award type

Named executive officerTime-vested (RSU)Performance-vested (PSU)Options / SARs% performance-vested
Joshua DeTillio$0$354,684$0100.0%
Jon Bates0239,6690100.0%
Thomas Vo0669,9500100.0%
Warren Hosseinion0505,9050100.0%

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

04

Outstanding equity awards at fiscal year-end 2025

ExecutiveAwardShares unvestedExercise priceMarket value unvested
Warren HosseinionPSU15,102—$2,489,172
Thomas VoPSU20,000—3,296,400
Michael ChangPSU5,000—824,120
Jon BatesPSU6,500—1,071,356
05

Incentive-plan design — the Compensation Discussion & Analysis

Nutex's compensation philosophy is to attract, motivate, and retain talented executives responsible for Nutex's success in an extremely competitive and rapidly evolving industry. The company strives to set compensation programs within the appropriate competitive framework based on achievement of financial results, individual contributions, and each executive's potential to enhance long-term stockholder value. Nutex generally seeks to be in the middle of its peer group for cash compensation and above average for equity-based compensation to align the interests of stockholders and NEOs.

CEO STI target (% of salary)—
CEO LTI target (% of salary)—
Independent consultantMercer
Clawback policytrue
Anti-hedgingtrue
Anti-pledgingtrue
06

Say-on-pay — recent advisory votes

Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20262026-04-232,505,375126,61211,22094.79%Passed
20252025-07-142,556,545226,34216,71891.87%Passed
20242024-06-1722,676,4495,845,536434,77978.31%Passed
20232023-06-29357,154,47872,863,958268,91883%Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.

Say-on-pay — history, company's computation

Meeting yearMeeting dateApproval — company's computation
20262026-04-2394.79%a
20252025-07-1491.87%b
20242024-06-1778.31%c

a. Approved under the standard stated in the filing — “Abstentions will have the same effect as votes against this proposal.”.

b. Approved under the standard stated in the filing — “Failure to vote by proxy or to vote in person or an abstention from voting will have no effect on the outcome of the vote on the Amendment Proposal.”.

c. Approved under the standard stated in the filing — “If you vote to ABSTAIN on Proposal 2, your shares will not be voted FOR or AGAINST the proposal and will also not be counted as votes cast or shares voting on Proposal 2. As a result, voting to ABSTAIN will have no effect on the voting on Proposal 2.”.

Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

07

CEO pay ratio

Ratio (CEO : median employee)—
CEO total compensation—
Median employee compensation—
08

Director compensation — fiscal year 2025

DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Michael L. ReedIndependent · Lead Independent Director · Audit · Compensation · Nominating and Governance$207,608$70,000$0—$0$277,608
Cheryl GrenasIndependent · Compensation (Chair) · Nominating and Governance201,86970,0000—0271,869
Scott J. SaundersIndependent · Audit · Compensation · Nominating and Governance (Chair)198,34670,0000—0268,346
Mitchell CreemIndependent · Audit (Chair) · Compensation · Departed during FY188,768—0—0188,768
Frank E. JaumotIndependent · Audit (Chair) · Compensation · Nominating and Governance · Newly elected82,26970,0000—0152,269
Kelvin SpearsNot independent000—00
Thomas T. VoEmployee director · Board Chair000—00
Warren HosseinionEmployee director000—00
09

Board fee structure and ownership guideline

Annual cash retainer$150,000
Annual equity retainer$70,000
Per board meeting fee—
Committee chair fees (audit / comp / nom-gov)20,000 / 15,000 / 15,000
Stock ownership guideline—
09b

Total cost of the board

ComponentFY2025
Cash retainers and fees$878,860
Equity awards (grant-date value)$280,000
All other compensation$0
Total cost of the board$1,158,860

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Nutex Health2025Thomas Vo$1,000,000$669,950$0$0$2,197,420

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

10d

Frequently asked questions

Who was the highest-paid executive at Nutex Health in fiscal 2025?
As disclosed, Thomas Vo (Chief Executive Officer and Chairman of the Board) was the highest-paid executive at Nutex Health in fiscal 2025, with total compensation of $2,197,420.
How did shareholders vote on Nutex Health's executive compensation?
As disclosed, 94.79% of shareholders supported Nutex Health's executive compensation in the latest say-on-pay vote.
How much does Nutex Health spend in total on board compensation for fiscal 2025?
As disclosed, Nutex Health reported total board compensation of $1,158,860 for fiscal 2025.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

11

Source register

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, Thomas VoDEF 14A2026-03-130001628280-26-017681Section “Summary Compensation Table” · page 30. As printed: 2,197,420. Filing ↗machine: t12 · r3 · c13 · span 360351–360360
2Section 01, Warren HosseinionDEF 14A2026-03-130001628280-26-017681Section “Summary Compensation Table” · page 30. As printed: 1,705,421. Filing ↗machine: t12 · r7 · c13 · span 371576–371585
3Section 01, Joshua DeTillioDEF 14A2026-03-130001628280-26-017681Section “Summary Compensation Table” · page 30. As printed: 952,132. Filing ↗machine: t12 · r18 · c12 · span 398213–398220
4Section 01, Jon BatesDEF 14A2026-03-130001628280-26-017681Section “Summary Compensation Table” · page 30. As printed: 923,205. Filing ↗machine: t12 · r11 · c12 · span 382228–382235
5Section 01, Michael ChangDEF 14A2026-03-130001628280-26-017681Section “Summary Compensation Table” · page 30. As printed: 716,585. Filing ↗machine: t12 · r22 · c13 · span 409266–409273
6Section 01, Wesley BamburgDEF 14A2026-03-130001628280-26-017681Section “Summary Compensation Table” · page 30. As printed: 105,972. Filing ↗machine: r15 · c21 · span 393015–393022
7Section 03, Joshua DeTillio PSUDEF 14A2026-03-130001628280-26-017681Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t12 · r18 · c5 · span 396370–396377
8Section 03, Jon Bates PSUDEF 14A2026-03-130001628280-26-017681Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t12 · r11 · c5 · span 380794–380801
9Section 03, Michael Chang OTHERDEF 14A2026-03-130001628280-26-017681Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t12 · r22 · c5 · span 407439–407446
10Section 03, Thomas Vo PSUDEF 14A2026-03-130001628280-26-017681Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t12 · r3 · c5 · span 358316–358323
11Section 03, Warren Hosseinion PSUDEF 14A2026-03-130001628280-26-017681Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t12 · r7 · c5 · span 369749–369756
12Section 07, pay ratioDEF 14A2026-03-130001628280-26-017681Section “CEO Pay Ratio”. As printed: —. Filing ↗
13Section 08, Michael L. ReedDEF 14A2026-03-130001628280-26-017681Section “Director Compensation”. As printed: 277,608. Filing ↗machine: t7 · r5 · c3 · span 242985–243165
14Section 08, Cheryl GrenasDEF 14A2026-03-130001628280-26-017681Section “Director Compensation”. As printed: 271,869. Filing ↗machine: t7 · r3 · c3 · span 240379–240559
15Section 08, Scott J. SaundersDEF 14A2026-03-130001628280-26-017681Section “Director Compensation”. As printed: 268,346. Filing ↗machine: t7 · r4 · c3 · span 241683–241863
16Section 08, Mitchell CreemDEF 14A2026-03-130001628280-26-017681Section “Director Compensation”. As printed: 188,768. Filing ↗machine: t6 · r5 · c2 · span 244288–244468
17Section 08, Frank E. JaumotDEF 14A2026-03-130001628280-26-017681Section “Director Compensation”. As printed: 152,269. Filing ↗machine: t7 · r2 · c3 · span 239038–239259
18Section 08, Kelvin SpearsDEF 14A2026-03-130001628280-26-017681Section “Director Compensation”. As printed: 0. Filing ↗
19Section 08, Thomas T. VoDEF 14A2026-03-130001628280-26-017681Section “Director Compensation”. As printed: 0. Filing ↗
20Section 08, Warren HosseinionDEF 14A2026-03-130001628280-26-017681Section “Director Compensation”. As printed: 0. Filing ↗
21Section 02, Pamela W. Montgomery 2026-03-13Form 42026-03-160001919434-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
22Section 02, Kelvin Spears 2026-03-17Form 42026-03-180002018803-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
23Section 02, Warren Hosseinion 2026-03-19Form 42026-03-230001438327-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
24Section 02, Frank E. Jaumot 2026-03-20Form 42026-03-230001303609-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
25Section 02, Thomas T. Vo 2026-04-09Form 42026-04-100001919945-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
26Section 02, Cheryl Grenas 2026-04-23Form 42026-04-240001920511-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
27Section 02, Frank E. Jaumot 2026-04-23Form 42026-04-240001303609-26-000003Insider equity transaction reported since the proxy statement. Filing ↗
28Section 02, Scott J. Saunders 2026-04-23Form 42026-04-240002018971-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
29Section 02, Michael L. Reed 2026-04-23Form 42026-04-240001922252-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
30Section 02, Thomas T. Vo 2026-05-28Form 42026-05-290001919945-26-000003Insider equity transaction reported since the proxy statement. Filing ↗
31Section 02, Kelvin Spears 2026-06-04Form 42026-06-040002018803-26-000003Insider equity transaction reported since the proxy statement. Filing ↗
32Section 02, Michael L. Reed 2026-07-31Form 42026-08-030001922252-26-000003Insider equity transaction reported since the proxy statement. Filing ↗
33Section 02, Scott J. Saunders 2026-07-31Form 42026-08-030002018971-26-000003Insider equity transaction reported since the proxy statement. Filing ↗
34Section 02, Cheryl Grenas 2026-07-31Form 42026-08-030001920511-26-000003Insider equity transaction reported since the proxy statement. Filing ↗
35Section 02, Frank E. Jaumot 2026-07-31Form 42026-08-030001303609-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
36Section 02, Scott J. Saunders 2026-09-18Form 42026-09-180002018971-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
37Section 06, 2026 voteForm 8-K2026-04-230001628280-26-026828Item 5.07 · say-on-pay result. As reported: 94.79% (votes for as printed: 2,505,375). Filing ↗
38Section 06, 2025 voteForm 8-K2025-07-160001628280-25-035002Item 5.07 · say-on-pay result. As reported: 91.87% (votes for as printed: 2,556,545). Filing ↗
39Section 06, 2024 voteForm 8-K2024-06-180001079973-24-000910Item 5.07 · say-on-pay result. As reported: 78.31% (votes for as printed: 22,676,449). Filing ↗
40Section 01 trend, Δ column (computed)Computed——Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1)
41Section 03b vehicle mix (computed)Computed——RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio
42Section 09b board cost (computed)Computed——Cash 878,860 + equity 280,000 + all other 0 = 1,158,860, summed across the director compensation table rows.machine: formula: Σ = 1,158,860
43Nutex Health (subject), Section 10b CEO totalDEF 14A2026-03-130001628280-26-017681CEO total compensation as printed in Nutex Health's own proxy. As printed: 2,197,420. Filing ↗machine: t12 · r3 · c13 · span 360351–360360

The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.

You'll confirm on The Pay Desk's sign-up page.